Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer

PURPOSE: The 21-gene recurrence score (RS) assay is prognostic among women with early-stage estrogen receptor–positive (ER+) and human epidermal growth factor receptor 2–negative (HER2−) breast cancer and is used to inform recommendations for chemotherapy. Women ≤ 40 years of age represent a minorit...

Descripción completa

Detalles Bibliográficos
Autores principales: Poorvu, Philip D., Gelber, Shari I., Rosenberg, Shoshana M., Ruddy, Kathryn J., Tamimi, Rulla M., Collins, Laura C., Peppercorn, Jeffrey, Schapira, Lidia, Borges, Virginia F., Come, Steven E., Warner, Ellen, Jakubowski, Debbie M., Russell, Christy, Winer, Eric P., Partridge, Ann H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048163/
https://www.ncbi.nlm.nih.gov/pubmed/31809240
http://dx.doi.org/10.1200/JCO.19.01959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048163/
https://www.ncbi.nlm.nih.gov/pubmed/31809240
http://dx.doi.org/10.1200/JCO.19.01959

Ejemplares similares